PHARMADRUG INC - LMLLF STOCK NEWS

Welcome to our dedicated page for PHARMADRUG news (Ticker: LMLLF), a resource for investors and traders seeking the latest updates and insights on PHARMADRUG stock.

PharmaDrug Inc. (LMLLF) is a specialty pharmaceutical company focused on research, development, and commercialization of controlled-substances, natural medicines, and previously approved drugs. The company's subsidiary, SecureDose Synthetics Inc., has engaged with Chiral Labs to develop a novel cocaine manufacturing process. With a goal to provide safe supply programs and revolutionize the pharmaceutical supply chain, PharmaDrug is committed to developing biosynthetic drugs to combat substance abuse and contaminated street drugs.

05/02/2024 04:40 PM

News

PharmaDrug Announces Director Appointment and Resignation

Rhea-AI Summary

PharmaDrug Inc. announces the appointment of Zalman Goldman to its board of directors, with a background in addiction and recovery, to advance the company's mission in drug research and commercialization. Concurrently, Nickolai Vassev resigns from the board. Mr. Goldman brings valuable experience to the company, receiving 500,000 stock options as part of his appointment.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

7.88%

Tags

05/01/2024 08:50 AM

News

PharmaDrug's Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine

Rhea-AI Summary

PharmaDrug's Sairiyo Therapeutics has finished the clinical and regulatory package for a Phase 1 study of their reformulated cepharanthine in Australia. This patented drug, PD-001, aims to treat infectious diseases and oncology. Sairiyo will conduct the study in Australia to benefit from drug development incentives, planning to submit an Investigational New Drug application to the FDA afterward.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

18.89%

Tags

04/16/2024 08:44 AM

News

PharmaDrug's SecureDose Announces the Advancement of Process Development of Its Biosynthetic Formulation of Pharmaceutical Grade Cocaine

Rhea-AI Summary

PharmaDrug's SecureDose partners with Chiral Labs to advance novel cocaine manufacturing process, aiming to develop biosynthetic pharmaceutical-grade cocaine for safe supply programs. The project includes process refinement, test batch production, and potential commercial manufacturing collaboration. The agreement involves a fee rate of CAD 60,000 per month with an anticipated completion timeline of seven to nine months.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

5.24%

Tags

03/13/2024 07:30 AM

News

PharmaDrug's SecureDose Announces Filing of US Provisional Patent for Manufacturing Method for Biosynthetic Pharmaceutical Grade Cocaine

Rhea-AI Summary

PharmaDrug Inc. initiates a project to develop a novel manufacturing method for commercial-scale cocaine production to support safe supply programs. The company files a patent for a biosynthetic chemistry method aiming to revolutionize the supply chain, potentially generating new revenue streams through global partnerships. PharmaDrug emphasizes harm reduction and the importance of biosynthetic versions of substances for a regulated pharmaceutical supply chain.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-6.98%

Tags

02/27/2024 08:00 AM

News

PharmaDrug Appoints Current Board Member Dr. David Kideckel as Chairman

Rhea-AI Summary

PharmaDrug Inc. appoints Dr. David Kideckel as Chairman of the Board, signaling a strategic shift towards clinical trials and drug development. With a strong background in the pharmaceutical industry, Dr. Kideckel's appointment aims to drive growth and innovation within the company.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-11.39%

Tags

02/14/2024 08:25 AM

News

PharmaDrug's Sairiyo Successfully Demonstrates Ability to Manufacture Cepharanthine (PD-001) for Human Clinical Studies

Rhea-AI Summary

PharmaDrug Inc. plans to pursue regulatory filings for a Phase I/II clinical study for its reformulated enteric coated version of orally bioavailable cepharanthine (PD-001) as a potential treatment for oncology and infectious diseases. The successful completion of manufacturing activities with Genvion Corporation enables future filings to Australia's TGA and the FDA. The Company aims to conduct clinical studies in the second quarter of 2024, with a focus on regulatory applications for human safety trials in Australia.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-10.42%

Tags

02/12/2024 08:44 AM

News

PharmaDrug Inc. Engages Investor Relations and Marketing Service Providers

Rhea-AI Summary

PharmaDrug Inc. partners with Outside The Box Capital Inc. for marketing and distribution services.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-14.74%

Tags

02/08/2024 04:30 PM

News

PharmaDrug Inc. Announces Successful Closing of Non-Brokered Private Placement

Rhea-AI Summary

PharmaDrug Inc. has closed a non-brokered private placement, raising $326,000 in total gross proceeds. The company issued 6,520,000 units at a purchase price of $0.05 per unit. Each unit consists of one common share and one-half of one common share purchase warrant. The proceeds will be used for general corporate purposes, and the securities issued are subject to a hold period of four months and one day.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

18.75%

Tags

10/20/2023 02:03 PM

News

PharmaDrug Announces Share Consolidation and Change to Chief Financial Officer

Rhea-AI Summary

PharmaDrug Inc. announces share consolidation and new CFO appointment

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

09/19/2023 04:05 PM

News

PharmaDrug Announces Amendment to Shareholder Meeting Matter

Rhea-AI Summary

PharmaDrug Inc. announces Mr. Daniel Cohen will not be standing for re-election as a director and will be replaced by Mr. Robert J. Steen. Management recommends voting for the approval of Mr. Steen as a director.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

FAQ

What is the current stock price of PHARMADRUG (LMLLF)?

The current stock price of PHARMADRUG (LMLLF) is $0.00855 as of December 20, 2024.

What is the market cap of PHARMADRUG (LMLLF)?

The market cap of PHARMADRUG (LMLLF) is approximately 1.2M.

What is PharmaDrug Inc. focused on?

PharmaDrug Inc. is focused on the research, development, and commercialization of controlled-substances, natural medicines, and previously approved drugs.

Who is PharmaDrug Inc.'s subsidiary engaged with for developing a novel cocaine manufacturing process?

PharmaDrug Inc.'s subsidiary, SecureDose Synthetics Inc., is engaged with Chiral Labs for the development of a novel cocaine manufacturing process.

What is PharmaDrug Inc.'s goal regarding safe supply programs?

PharmaDrug Inc.'s goal is to develop biosynthetic drugs for safe supply programs to combat substance abuse and contaminated street drugs.

How does PharmaDrug Inc. aim to revolutionize the pharmaceutical supply chain?

PharmaDrug Inc. aims to provide biosynthetic drugs that offer safe supply and new revenue opportunities through global partnerships and out-licensing.